Analyzing Advaxis (ADXS) & Its Rivals
Advaxis (NASDAQ: ADXS) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Advaxis to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.
Earnings and Valuation
This table compares Advaxis and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Advaxis||$14.01 million||-$93.95 million||-1.39|
|Advaxis Competitors||$207.80 million||-$2.30 million||2.07|
Advaxis’ rivals have higher revenue and earnings than Advaxis. Advaxis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent ratings and target prices for Advaxis and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Advaxis currently has a consensus target price of $21.00, suggesting a potential upside of 560.38%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.51%. Given Advaxis’ stronger consensus rating and higher probable upside, equities analysts clearly believe Advaxis is more favorable than its rivals.
Institutional and Insider Ownership
48.0% of Advaxis shares are held by institutional investors. Comparatively, 46.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.2% of Advaxis shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Advaxis and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Advaxis has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Advaxis’ rivals have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.
Advaxis beats its rivals on 7 of the 12 factors compared.
Advaxis Company Profile
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.